1. Single-cell RNA-seq-based proteogenomics identifies glioblastoma-specific transposable elements encoding HLA-I-presented peptides.
- Author
-
Bonté PE, Arribas YA, Merlotti A, Carrascal M, Zhang JV, Zueva E, Binder ZA, Alanio C, Goudot C, and Amigorena S
- Subjects
- DNA Transposable Elements, Humans, Peptides genetics, RNA-Seq, Glioblastoma genetics, Histocompatibility Antigens Class I genetics, Proteogenomics
- Abstract
We analyze transposable elements (TEs) in glioblastoma (GBM) patients using a proteogenomic pipeline that combines single-cell transcriptomics, bulk RNA sequencing (RNA-seq) samples from tumors and healthy-tissue cohorts, and immunopeptidomic samples. We thus identify 370 human leukocyte antigen (HLA)-I-bound peptides encoded by TEs differentially expressed in GBM. Some of the peptides are encoded by repeat sequences from intact open reading frames (ORFs) present in up to several hundred TEs from recent long interspersed nuclear element (LINE)-1, long terminal repeat (LTR), and SVA subfamilies. Other HLA-I-bound peptides are encoded by single copies of TEs from old subfamilies that are expressed recurrently in GBM tumors and not expressed, or very infrequently and at low levels, in healthy tissues (including brain). These peptide-coding, GBM-specific, highly recurrent TEs represent potential tumor-specific targets for cancer immunotherapies., Competing Interests: Declaration of interests C.A. is a consultant for Biotherapy Partners. S.A. is shareholder and consultant for Mnemo Therapeutics. P.-E.B., Y.A.A., A.M., E.Z., and C.G. are consultants for Mnemo Therapeutics. A patent related to this work has been deposited under number EP22305355 in European Patent Application., (Copyright © 2022 Institut Curie. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF